A quandary - good to claim safety from over 1000 patients, but has the product changed enough to distance from historical failures?
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-303
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
0.005(0.36%) |
Mkt cap ! $1.569B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.41 | $1.38 | $592.4K | 424.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 53314 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 12089 | 6 |
View Market Depth
| Last trade - 10.21am 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |